Seperately Filed Delaying Amendment Under Securities Act Rule 473 to Delay Effectiveness of a 1933 Act Registration Statement (del Am)
03 Aprile 2023 - 12:18PM
Edgar (US Regulatory)
AMBRX BIOPHARMA INC.
10975 North Torrey Pines Road
La
Jolla, CA 92037
March 31, 2023
VIA
EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3 (File
No. 333-271008)
Ladies and Gentlemen:
Reference is made to the Registration Statement on Form S-3 (File
No. 333-271008) filed with the Securities and Exchange Commission (the Commission) by Ambrx Biopharma Inc. on March 30, 2023 (the Registration Statement). Pursuant to Rule
473(c) of the Securities Act of 1933, as amended (the Act), the following delaying amendment, prescribed by Rule 473(a) of the Act, is hereby incorporated into the facing page of the Registration Statement:
The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall
become effective on such date as the Securities and Exchange Commission acting pursuant to said Section 8(a), may determine.
Sincerely,
|
|
|
AMBRX BIOPHARMA INC. |
|
|
By: |
|
/s/ Sonja Nelson |
Name: Sonja Nelson |
Title: Chief Financial and Operating Officer |
cc: |
Carlos Ramirez, Cooley LLP |
Grafico Azioni Ambrx Biopharma (NASDAQ:AMAM)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Ambrx Biopharma (NASDAQ:AMAM)
Storico
Da Giu 2023 a Giu 2024